90 related articles for article (PubMed ID: 16100046)
1. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Frank JS; Grijalva VR; Ganesh VK; Mishra VK; Palgunachari MN; Fogelman AM
Circ Res; 2005 Sep; 97(6):524-32. PubMed ID: 16100046
[TBL] [Abstract][Full Text] [Related]
2. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
[TBL] [Abstract][Full Text] [Related]
3. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein A-I mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
[TBL] [Abstract][Full Text] [Related]
5. Potential clinical utility of high-density lipoprotein-mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2006 Aug; 17(4):440-4. PubMed ID: 16832169
[TBL] [Abstract][Full Text] [Related]
6. Oral amphipathic peptides as therapeutic agents.
Reddy ST; Anantharamaiah GM; Navab M; Hama S; Hough G; Grijalva V; Garber DW; Datta G; Fogelman AM
Expert Opin Investig Drugs; 2006 Jan; 15(1):13-21. PubMed ID: 16370930
[TBL] [Abstract][Full Text] [Related]
7. ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity.
Datta G; Chaddha M; Handattu SP; Palgunachari MN; Nayyar G; Garber DW; Gupta H; White CR; Anantharamaiah GM
Adv Exp Med Biol; 2010; 660():1-4. PubMed ID: 20221865
[TBL] [Abstract][Full Text] [Related]
8. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Hama S; Hough G; Reddy ST; Frank JS; Garber DW; Handattu S; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1426-32. PubMed ID: 15845909
[TBL] [Abstract][Full Text] [Related]
9. Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
Qin S; Kamanna VS; Lai JH; Liu T; Ganji SH; Zhang L; Bachovchin WW; Kashyap ML
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):334-43. PubMed ID: 22308547
[TBL] [Abstract][Full Text] [Related]
10. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
Aviram M; Rosenblat M; Bisgaier CL; Newton RS; Primo-Parmo SL; La Du BN
J Clin Invest; 1998 Apr; 101(8):1581-90. PubMed ID: 9541487
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.
Navab M; Anantharamaiah GM; Hama S; Garber DW; Chaddha M; Hough G; Lallone R; Fogelman AM
Circulation; 2002 Jan; 105(3):290-2. PubMed ID: 11804981
[TBL] [Abstract][Full Text] [Related]
12. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
Choudhury RP; Rong JX; Trogan E; Elmalem VI; Dansky HM; Breslow JL; Witztum JL; Fallon JT; Fisher EA
Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1904-9. PubMed ID: 15319266
[TBL] [Abstract][Full Text] [Related]
13. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
[TBL] [Abstract][Full Text] [Related]
14. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females.
Ferretti G; Bacchetti T; Moroni C; Savino S; Liuzzi A; Balzola F; Bicchiega V
J Clin Endocrinol Metab; 2005 Mar; 90(3):1728-33. PubMed ID: 15613429
[TBL] [Abstract][Full Text] [Related]
15. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
[TBL] [Abstract][Full Text] [Related]
16. Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice.
Macdonald DL; Terry TL; Agellon LB; Nation PN; Francis GA
Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1583-8. PubMed ID: 12855483
[TBL] [Abstract][Full Text] [Related]
17. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
Mertens A; Verhamme P; Bielicki JK; Phillips MC; Quarck R; Verreth W; Stengel D; Ninio E; Navab M; Mackness B; Mackness M; Holvoet P
Circulation; 2003 Apr; 107(12):1640-6. PubMed ID: 12668499
[TBL] [Abstract][Full Text] [Related]
18. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice.
She ZG; Zheng W; Wei YS; Chen HZ; Wang AB; Li HL; Liu G; Zhang R; Liu JJ; Stallcup WB; Zhou Z; Liu DP; Liang CC
Circ Res; 2009 May; 104(10):1160-8. PubMed ID: 19359600
[TBL] [Abstract][Full Text] [Related]
19. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Hama S; Hough G; Fogelman AM
Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
[TBL] [Abstract][Full Text] [Related]
20. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.
Imaizumi S; Grijalva V; Navab M; Van Lenten BJ; Wagner AC; Anantharamiah GM; Fogelman AM; Reddy ST
Drug Metab Lett; 2010 Aug; 4(3):139-48. PubMed ID: 20642447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
